Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University and a member of the scientific advisory board at Zentalis (ZNTL), has emerged as a top candidate to serve as the next director of the National Cancer Institute, STAT News’ Matthew Herper and Angus Chen report, citing multiple sources with direct knowledge of the situation. Cancer scientists have expressed relief that Letai would lead the cancer research office, as they describe him as both kind and a highly qualified scientist, the authors note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals Announces New Chief Legal Officer
- Zentalis CLO Andrea Paul to depart, James Bucher to succeed
- Zentalis price target lowered to $5 from $6 at Wells Fargo
- Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism